Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to ...

Weight-loss medication like Semaglutide and Tirzepatide has seen a rise in demand, causing a boom in sales. This exploding ...

Here are some of the drugs that are predicted to become blockbusters in the next few years, according to Clarivate's latest ...

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care ...

Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...

Dr. Mehmet Furkan Burak said people who have lost weight and then gained it again can feel guilt or shame and blame ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

The contents of cannabis plants are both psychoactive and nutritious. Today, extracts from the cannabis plant are ingredients ...

Structure Therapeutics, Inc. Sponsored ADR (GPCR) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Annabel Samimy.Stay ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...